tetranor-PGEM

tetranor-PGEM (CAS No.: 24769-56-0) is a stable end-product metabolite of prostaglandin E2 (PGE2) and is widely utilized as a noninvasive biomarker for assessing systemic PGE2 production and inflammatory status in biological systems. As a downstream metabolite generated through enzymatic degradation of PGE2, tetranor-PGEM reflects the activity of cyclooxygenase-mediated arachidonic acid pathways and is therefore closely linked to key inflammatory signaling cascades, including those involving COX-2 and prostaglandin E synthases. Elevated levels of tetranor-PGEM, particularly in urine, have been associated with a range of pathological conditions, including colorectal, ovarian, and prostate cancers, as well as metabolic and inflammatory disorders such as obesity, smoking-related inflammation, and diabetic nephropathy. In addition, its levels have been correlated with disease progression and metastatic potential, including lung metastasis in breast cancer, highlighting its utility in translational oncology research. While tetranor-PGEM itself is not typically characterized by direct pharmacological activity in terms of receptor binding or inhibition constants, its measurable concentrations in the nanomolar to micromolar range in biological samples provide a robust readout for pathway activation. In experimental settings, it is commonly quantified in cell culture supernatants, animal models, and clinical specimens to monitor inflammatory responses, evaluate drug efficacy targeting prostaglandin pathways, and support biomarker discovery studies, with specific assay conditions and sample handling tailored to the experimental design.